Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16142012 | 0.91 | CYP4F2 (0.45) | CYP4F2CYP4A11LMNANPSR1 | |
| SCHEMBL20617478 | 0.85 | CYP4F2 (0.50) | CYP4F2CYP4A11LMNAMEN1NPY1R | |
| SCHEMBL20601947 | 0.83 | CYP4F2 (0.49) | CYP4F2CYP4A11LMNAMEN1NPY1R | |
| SCHEMBL356203 | 0.80 | CYP4F2 (0.49) | CYP4F2CYP4A11LMNAALDH1A1PKM | |
| SCHEMBL6268373 | 0.79 | CYP4F2 (0.70) | CYP4F2CYP4A11MEN1KMT2ANPSR1 | |
| SCHEMBL21963873 | 0.77 | CYP4F2 (0.40) | CYP4F2CYP4A11LMNANPSR1 | |
| SCHEMBL8790982 | 0.76 | CYP4F2 (0.44) | CYP4F2CYP4A11 | |
| SCHEMBL9886223 | 0.75 | CYP4F2 (0.51) | CYP4F2CYP4A11LMNAALDH1A1PKM | |
| SCHEMBL31369221 | 0.71 | CYP4F2 (0.36) | CYP4F2CYP4A11LMNANPSR1 | |
| SCHEMBL16112159 | 0.70 | CYP4F2 (0.36) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-11603373-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603373-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | CYP4F2 621/4885CYP4A11 1816/4885LMNA 4869/4885 |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | CYP4F2 621/4885CYP4A11 1816/4885LMNA 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.